Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy | Journal of the American Heart Association
BackgroundCardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we …